Login to Your Account



Clinic Roundup


Thursday, July 25, 2013

• Insite Vision Inc., of Alameda, Calif., reported top-line results from a Phase III trial of Azasite Plus and Dexasite for moderate-to-severe blepharitis. The drugs did not meet the primary endpoint of complete resolution of all signs and symptoms. They did show statistically significant improvements in signs and symptoms at 15 days. Insite Vision will meet with the FDA on Aug. 19, 2013 to review the results of the DOUBle Phase III study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription